Holen Sie sich die Stockscreener-App
22.88
2.10%
-0.49
Handel nachbörslich:
22.90
0.02
+0.09%
Schlusskurs vom Vortag:
$23.37
Offen:
$23.37
24-Stunden-Volumen:
1.81M
Relative Volume:
1.96
Marktkapitalisierung:
$2.51B
Einnahmen:
$14.09M
Nettoeinkommen (Verlust:
$-176.94M
KGV:
-10.64
EPS:
-2.15
Netto-Cashflow:
$-141.24M
1W Leistung:
+6.42%
1M Leistung:
+19.85%
6M Leistung:
+41.58%
1J Leistung:
+9.26%
1-Tages-Spanne:
$22.21
$23.89
1-Wochen-Bereich:
$21.00
$24.23
52-Wochen-Spanne:
$15.19
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Firmenname
Newamsterdam Pharma Company Nv
Sektor
Branche
Telefon
35 206 2971
Adresse
GOOIMEER 2-35, NARRDEN
Vergleichen Sie NAMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
22.88 | 2.51B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-15 | Eingeleitet | TD Cowen | Buy |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-18 | Eingeleitet | Guggenheim | Buy |
| 2024-01-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-30 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
A better buy-in window may exist right now for NewAmsterdam Pharma Company NV (NAMS) - SETE News
Newamsterdam pharma director James Topper buys $84,203 in shares By Investing.com - Investing.com South Africa
Newamsterdam pharma director James Topper buys $84,203 in shares - Investing.com
New Amsterdam Pharma chief accounting officer sells $3.06 million in shares - Investing.com Australia
New Amsterdam Pharma chief accounting officer sells $3.06 million in shares By Investing.com - Investing.com South Africa
William Blair Has Negative Forecast for NAMS Q1 Earnings - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Price Target Raised to $52.00 - Defense World
(NAMS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib - Seeking Alpha
NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution (NASDAQ:NAMS) - Seeking Alpha
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
NewAmsterdam Pharma’s 2024 Financial Results and Clinical Progress - TipRanks
7 Analysts Have This To Say About NewAmsterdam Pharma - Benzinga
Scotiabank raises NewAmsterdam Pharma target to $52 - Investing.com India
Scotiabank raises NewAmsterdam Pharma target to $52 By Investing.com - Investing.com South Africa
Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence - TipRanks
NewAmsterdam Pharma's Full-Year Net Loss Widens, Revenue Rises -February 26, 2025 at 08:27 am EST - Marketscreener.com
Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Revenue $45.6M, vs. FactSet Est of $33.8M - Marketscreener.com
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
NewAmsterdam Pharma Co N.V. SEC 10-K Report - TradingView
Can NewAmsterdam's Obicetrapib Reshape Cardiovascular Treatment? Phase 3 Results Show 49% LDL-C Reduction - StockTitan
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - The Manila Times
NewAmsterdam Pharma Company N.V. (NAMS): Among the Oversold Biotech Stocks to Buy Now - Insider Monkey
10 Oversold Biotech Stocks to Buy Now - Insider Monkey
How to Take Advantage of moves in (NAMSW) - Stock Traders Daily
Newamsterdam pharma COO sells shares worth $1.8 million - Investing.com India
Newamsterdam pharma COO sells shares worth $1.8 million By Investing.com - Investing.com Nigeria
How To Trade (NAMS) - Stock Traders Daily
Mirae Asset Global Investments Co. Ltd. Makes New Investment in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease - Yahoo Finance
NewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
abrdn plc Raises Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Newamsterdam pharma CFO sells shares worth $1.5 million - MSN
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Where are the Opportunities in (NAMS) - Stock Traders Daily
Make Informed Decisions with NewAmsterdam Pharma Company NV (NAMS) Stock Updates - The News Heater
Ratios Uncovered: Breaking Down NewAmsterdam Pharma Company NV (NAMS)’s Trailing Twelve Months Metrics - The Dwinnex
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - AOL
Results from NewAmsterdam Pharma Company NV (NAMS) show risk - US Post News
China Universal Asset Management Co. Ltd. Takes Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
H.C. Wainwright initates NewAmsterdam Pharma Company NV (NAMS) rating to a Buy - Knox Daily
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 4.1%Still a Buy? - MarketBeat
NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan
JPMorgan Chase & Co. Increases Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by Moody Aldrich Partners LLC - MarketBeat
How To Trade (NAMSW) - Stock Traders Daily
Finanzdaten der Newamsterdam Pharma Company Nv-Aktie (NAMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.14%
2.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):